<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/21CFR206.html">Part 206
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 206.7  Exemptions.
                            </h3>
                            <p class="depth1"><em>(a)</em> The following classes of drug products are exempt from  requirements of this part:</p><p class="depth2"><em>(1)</em> Drug products intended for use in a clinical investigation under  section 505(i) of the act, but not including drugs distributed under a  treatment IND under part 312 of this chapter or distributed as part of a  nonconcurrently controlled study. Placebos intended for use in a  clinical investigation are exempt from the requirements of this part if  they are designed to copy the active drug products used in that  investigation.</p><p class="depth2"><em>(2)</em> Drugs, other than reference listed drugs, intended for use in  bioequivalence studies.</p><p class="depth2"><em>(3)</em> Drugs that are extemporaneously compounded by a licensed  pharmacist, upon receipt of a valid prescription for an individual  patient from a practitioner licensed by law to prescribe or administer  drugs, to be used solely by the patient for whom they are prescribed.</p><p class="depth2"><em>(4)</em> Radiopharmaceutical drug products.</p><p class="depth1"><em>(b)</em> Exemption of drugs because of size or unique physical  characteristics:</p><p class="depth2"><em>(1)</em> For a drug subject to premarket approval, FDA may provide an  exemption from the requirements of Sec. 206.10 upon a showing that the  product's size, shape, texture, or other physical characteristics make  imprinting technologically infeasible or impossible.</p><p class="depth3"><em>(i)</em> Exemption requests for products with approved applications shall  be made in writing to the appropriate review division in the Center for  Drug Evaluation and Research (CDER), Food and Drug Administration, 5901- B Ammendale Rd., Beltsville, MD 20705-1266 or the Center for Biologics  Evaluation and Research (CBER), Food and Drug Administration, 1401  Rockville Pike, suite 200N, Rockville, MD 20852-1448. If FDA denies the  request, the holder of the approved application will have 1 year after  the date of an agency denial to imprint the drug product.</p><p class="depth3"><em>(ii)</em> Exemption requests for products that have not yet received  approval shall be made in writing to the appropriate review division in  CDER or CBER.</p><p class="depth2"><em>(2)</em> Any product not subject to premarket approval is exempt from the  requirement of Sec. 206.10 if, based on the product's size, shape,  texture, or other physical characteristics, the manufacturer or  distributor of the product is prepared to demonstrate that imprinting  the dosage form is technologically infeasible or impossible.</p><p class="depth1"><em>(c)</em> For drugs that are administered solely in controlled health care  settings and not provided to patients for self-administration, sponsors  may submit requests for exemptions from the requirements of this rule.  Controlled settings include physicians' offices and other health care  facilities. Exemption requests should be submitted in writing to the  appropriate review division in CDER or CBER.  [58 FR 47958, Sept. 13, 1993, as amended at 70 FR 14981, Mar. 24, 2005;  74 FR 13112, Mar. 26, 2009]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
